Metastatic Focus Size Determination via mRNA Quantitation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining cancer metastasis in lymph nodes are subjective and lack objectivity, failing to accurately assess the extent of cancer spread due to reliance on expert skill and inability to quantify metastasis effectively.
Innovation Solution
A method and apparatus that quantify cytokeratin 19 mRNA in lymph node samples to determine the size of metastatic foci by comparing results with set thresholds, enabling objective classification of cancer metastasis as negative, weakly positive, or strongly positive.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If tissue diagnosis with microscopy is used to determine cancer metastasis extent, then expert skill can identify metastatic cells, but the determination is subjective and lacks objectivity
Solution Approach 1:
The patent replaces the mechanical/optical microscopy system with a molecular biology-based quantification system. Instead of visually examining tissue sections under a microscope, the invention uses mRNA extraction and quantification techniques to objectively measure metastatic cell presence through molecular markers, eliminating subjective visual assessment
Solution Approach 2:
The patent introduces mRNA molecules as intermediaries between the metastatic cells and the detection system. By quantifying specific mRNA transcripts from metastatic cells in the lymph node tissue, the system creates an objective molecular proxy that correlates with metastasis extent, replacing direct visual observation
2Difficulty of detecting and measuring
If microscopy-based tissue diagnosis is used, then visual inspection of stained sections can be performed, but it is difficult to obtain objective determination results
Solution Approach 1:
The patent changes the measurement parameter from visual characteristics (cell morphology, staining intensity) to molecular quantity (mRNA copy number or expression level). This parameter transformation enables objective quantification through numerical measurement rather than subjective visual assessment, while maintaining ease of detection through standardized molecular assays
3Reliability
If known metastasis diagnosis markers are used to diagnose presence of metastasis, then metastasis can be diagnosed, but the extent of metastasis cannot be determined
Solution Approach 1:
The patent implements a quantitative feedback mechanism where the amount of detected mRNA is measured and correlated with metastatic focus size. By establishing a relationship between mRNA quantity and physical metastasis extent, the system provides numerical feedback that enables precise quantification rather than merely qualitative presence/absence determination
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for accurate and objective determination of cancer metastasis extent by correlating mRNA quantitation results with metastatic focus size, providing a reliable method for classifying micro and macro metastasis.
Implementation Method 1
Methods and apparatuses for the amplification of nucleic acids, including e.g. the amplification of CK19 mRNA are known e.g. from EP 1 813 682
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A method which can objectively determine to what extent a cancer cell has metastasized to a lymph node, the method being a method for determining a size of a metastatic focus, including a step of quantitating a tumor marker mRNA in an assay sample prepared from a lymph node suspected of metastasis of a cancer cell, and a step of obtaining a size of a metastatic focus in the lymph node based on the quantitation result of the mRNA.